Clinical AI has an
evidence problem.
We started there.
Dasyante exists because we believe hospitals will never — and should never — act on machine-generated facts they can't trace. So we built the tracing first, and the intelligence around it.
Built in India, where the problem is largest.
India's cancer centers see some of the highest patient volumes in the world, with records that stretch across years, hospitals, and formats. That is exactly where longitudinal truth matters most — and where it is hardest to keep. We built Dasyante here, with the clinicians who live this problem, validating against real oncology workflows with a leading Indian cancer centre — a partnership we'll announce soon.
Trust first. Everything else follows.
Most clinical AI leads with capability and retrofits accountability. We think that ordering is backwards, and that the market will eventually agree. A system that shows its evidence, admits what it hasn't verified, and improves only through human-approved, revertable changes can be given real responsibility. One that can't, can't. That's the entire company in four sentences.
Early, and precise about it.
Dasyante is an early-stage company. The core pipeline is built and running. Clinical validation is underway with partner oncologists. We are raising a seed round to take the system from validated pipeline to deployed product inside our first hospitals.
If you want polished case studies, we're early for you — check back. If you want to shape what auditable clinical AI becomes, this is the moment to talk.
Early-stage · oncology beachhead · raising seed
Talk to a founder, not a funnel.
Hospitals and cancer networks: we'd like to run Dasyante on your archive, inside your walls. Investors: the seed deck is a conversation away. Engineers and clinicians who care about this problem: we read everything.